[HTML][HTML] Reply: Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis?
I Noth, M Olman - American journal of respiratory and critical care …, 2012 - atsjournals.org
We have with great interest read the article by Noth and colleagues from The Idiopathic
Pulmonary Fibrosis Clinical Research Network (IPFnet) in a recent issue of the Journal.
They report on the results from the Placebo-Controlled Randomized Trial of Warfarin in IPF
(ACE-IPF)(1). The ACE-IPF study was aborted before study endpoint due to a low probability
of benefit and an increase in mortality in the warfarintreated subjects (14 warfarin vs. 3
placebo deaths; P= 0.005). We compliment the researchers for a well-conducted study, but …
Pulmonary Fibrosis Clinical Research Network (IPFnet) in a recent issue of the Journal.
They report on the results from the Placebo-Controlled Randomized Trial of Warfarin in IPF
(ACE-IPF)(1). The ACE-IPF study was aborted before study endpoint due to a low probability
of benefit and an increase in mortality in the warfarintreated subjects (14 warfarin vs. 3
placebo deaths; P= 0.005). We compliment the researchers for a well-conducted study, but …
Is Warfarin the Right Anticoagulant in Idiopathic Pulmonary Fibrosis?/Reply
MD Elisabeth Bendstrup… - American Journal of …, 2012 - search.proquest.com
We have with great interest read the article by Noth and colleagues from The Idiopathic
Pulmonary Fibrosis Clinical Research Network (IPFnet) in a recent issue of the Journal.
They report on the results from the Placebo-Controlled Randomized Trial of Warfarin in IPF
(ACE-IPF)(1). The ACE-IPF study was aborted before study endpoint due to a low probability
of benefit and an increase in mortality in the warfarintreated subjects (14 warfarin vs. 3
placebo deaths; P= 0.005). We compliment the researchers for a well-conducted study, but …
Pulmonary Fibrosis Clinical Research Network (IPFnet) in a recent issue of the Journal.
They report on the results from the Placebo-Controlled Randomized Trial of Warfarin in IPF
(ACE-IPF)(1). The ACE-IPF study was aborted before study endpoint due to a low probability
of benefit and an increase in mortality in the warfarintreated subjects (14 warfarin vs. 3
placebo deaths; P= 0.005). We compliment the researchers for a well-conducted study, but …